Science Explorer Back to mapMap
Institution · National Cancer Center

Most cited papers from National Cancer Center

What are the most cited papers from National Cancer Center?

The most cited paper from National Cancer Center is "Cancer statistics in China, 2015" (Wanqing Chen, Rongshou Zheng, Peter D. Baade et al., 2016), with 18,026 citations. Next come "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review" (6,577) and "Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)" (6,023).

Showing 50 of 60 papers. Every paper with more than 524 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Cancer statistics in China, 2015 Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians Open access 25 Jan 2016 18,026
2 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review Hiroshi Maeda, Jun Wu, Tomohiro Sawa et al. · Journal of Controlled Release Mar 2000 6,577
3 Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy Open access2,467 authors 2 Jan 2016 6,023
4 Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria et al. · New England Journal of Medicine Open access 18 Nov 2017 5,475
5 Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine Open access 4 Jun 2017 3,322
6 First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer Benjamin J. Solomon, Tony S.K. Mok, Dong‐Wan Kim et al. · New England Journal of Medicine Open access 3 Dec 2014 3,251
7 Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC Suresh S. Ramalingam et al. · New England Journal of Medicine Open access 21 Nov 2019 2,933
8 Everolimus for Advanced Pancreatic Neuroendocrine Tumors James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine Open access 9 Feb 2011 2,877
9 Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi et al. · New England Journal of Medicine Open access 31 Oct 2007 2,547
10 Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Hansjochen Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology 17 Sep 2014 2,505
11 Comprehensive genomic profiles of small cell lung cancer Julie George et al. · Nature Open access 10 Jul 2015 2,448
12 Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang et al. · The Lancet Open access 12 Oct 2017 2,317
13 Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Shanu Modi et al. · New England Journal of Medicine Open access 11 Dec 2019 2,026
14 Immune evasion in cancer: Mechanistic basis and therapeutic strategies Dass S. Vinay et al. · Seminars in Cancer Biology Open access 5 Apr 2015 1,684
15 Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine Open access 29 May 2020 1,352
16 Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology Open access 30 Sep 2019 1,262
17 Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410 Walter John Curran, Rebecca Paulus, Corey Jay Langer et al. · JNCI Journal of the National Cancer Institute Open access 8 Sep 2011 1,248
18 Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012 Kyu‐Won Jung, Young‐Joo Won, Hyun-Joo Kong et al. · Cancer Research and Treatment Open access 3 Mar 2015 1,167
19 Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi et al. · The Lancet 3 Jun 2016 1,145
20 Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer Heather A. Wakelee, Moïshe Liberman, Terufumi Kato et al. · New England Journal of Medicine Open access 3 Jun 2023 1,142
21 TGF-β signaling in health, disease and therapeutics Ziqin Deng, Tao T. Fan, Xiao Chu et al. · Signal Transduction and Targeted Therapy Open access 21 Mar 2024 1,141
22 Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial Sung Hoon Noh, Sook Ryun Park, Han‐Kwang Yang et al. · The Lancet Oncology Open access 15 Oct 2014 1,090
23 Brain metastases Achal Singh Achrol, Robert Charles Rennert, Carey K. Anders et al. · Nature Reviews Disease Primers Review 17 Jan 2019 1,069
24 Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia et al. · New England Journal of Medicine Open access 4 Jun 2019 1,044
25 D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer Mitsuru Sasako, Takeshi Sano, Seiichiro Yamamoto et al. · New England Journal of Medicine Open access 30 Jul 2008 1,029
26 Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial Seung‐Yong Jeong et al. · The Lancet Oncology 15 May 2014 906
27 Identification of Genes Upregulated in ALK -Positive and EGFR/KRAS/ALK -Negative Lung Adenocarcinomas Hirokazu Okayama et al. · Cancer Research Open access 12 Nov 2011 906
28 Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine Open access 26 Aug 2020 856
29 Cuproptosis: mechanisms and links with cancers Jiaming Xie, Yannan Yang, Yibo Gao et al. · Molecular Cancer Open access 7 Mar 2023 821
30 Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer Yuanyuan Zhang, Hongyan Chen, Hongnan Mo et al. · Cancer Cell Open access 15 Oct 2021 818
31 Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang et al. · The Lancet Oncology Open access 11 Jan 2022 808
32 Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study Philip James Johnson et al. · Journal of Clinical Oncology 27 Aug 2013 780
33 The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome Jung Sub Lim, Michele Mietus‐Snyder, Annie Valente et al. · Nature Reviews Gastroenterology & Hepatology Review 6 Apr 2010 778
34 Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan Takuji Okusaka, Kohei Nakachi, Akira Fukutomi et al. · British Journal of Cancer Open access 13 Jul 2010 757
35 Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial Masatoshi Kudo et al. · Gut Open access 4 Dec 2019 739
36 Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy Tatsuhiro Shibata, Tsutomu Ohta, Kit I. Tong et al. · Proceedings of the National Academy of Sciences Open access 29 Aug 2008 733
37 Surgery Plus Chemotherapy Compared With Surgery Alone for Localized Squamous Cell Carcinoma of the Thoracic Esophagus: A Japan Clinical Oncology Group Study—JCOG9204 Nobutoshi Ando, Toshifumi Iizuka, Hiroko Ide et al. · Journal of Clinical Oncology 12 Dec 2003 731
38 Endoscopic submucosal dissection of early gastric cancer Takuji Gotoda, Hironori Yamamoto, Roy M. Soetikno · Journal of Gastroenterology Oct 2006 699
39 Gastric Cancer Surgery: Morbidity and Mortality Results From a Prospective Randomized Controlled Trial Comparing D2 and Extended Para-Aortic Lymphadenectomy—Japan Clinical Oncology Group Study 9501 Takeshi Sano, Mitsuru Sasako, Seiichiro Yamamoto et al. · Journal of Clinical Oncology 17 Jun 2004 679
40 Heterocyclic amines: Mutagens/carcinogens produced during cooking of meat and fish Takashi Sügimura, Keiji Wakabayashi, Hitoshi Nakagama et al. · Cancer Science Open access Apr 2004 673
41 A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201) Kenji Suzuki, Teruaki Koike, T. Asakawa et al. · Journal of Thoracic Oncology Open access 18 Feb 2011 664
42 Integrative Proteomic Characterization of Human Lung Adenocarcinoma Jun‐Yu Xu et al. · Cell Open access Jul 2020 658
43 Cancer survival in C hina, 2003–2005: A population‐based study Hongmei Zeng et al. · International Journal of Cancer Open access 20 Sep 2014 644
44 Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan Yuichiro Ohe, Yasuo Ohashi, Kaoru Kubota et al. · Annals of Oncology Open access 2 Nov 2006 638
45 Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project Megumi Hori, Tomohiro Matsuda, Akiko Shibata et al. · Japanese Journal of Clinical Oncology 3 Jul 2015 626
46 Improved Quality of Life Outcomes After Laparoscopy-Assisted Distal Gastrectomy for Early Gastric Cancer Young‐Woo Kim, Yong Hae Baik, Young Ho Yun et al. · Annals of Surgery 21 Oct 2008 609
47 Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen Yusuke Yoshioka, Nobuyoshi Kosaka, Yuki Konishi et al. · Nature Communications Open access 7 Apr 2014 607
48 Estimates of human fertility and pregnancy loss Michael J. Zinaman, E. D. Clegg, Charles Brown et al. · Fertility and Sterility Open access Mar 1996 591
49 Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality Jae Kwan Jun, Kui Son Choi, Hooyeon Lee et al. · Gastroenterology Open access 29 Jan 2017 578
50 Cancer Incidence and Incidence Rates in Japan in 2008: A Study of 25 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project Ayako Matsuda, Tomohiro Matsuda, Akiko Shibata et al. · Japanese Journal of Clinical Oncology 5 Feb 2014 574

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.